New Trasylol Label Tightens Kidney Warning, Restricts Usage
December 21, 2006
WASHINGTON - New safety warnings have been added to the Trasylol label, and the FDA has limited the type of situations where the drug may be used, according to a statement released by the federal agency.
The Dec. 15 release by the FDA noted that Trasylol, often given to patients prior to heart surgery to reduce bleeding, should only be given to patients at an increased risk of blood loss or blood transfusion. Additionally, the FDA has approved changes to the drug's warning label, indicating that those who receive injections of Trasylol face a possible risk of kidney damage.